Inhibitors of specific RBPs, such as LIN28, IGF2BPs, HuR, and Musashi, have shown efficacy in decreasing tumor growth, enhancing the differentiation of cancer cells, and reducing resistance to chemotherapy. This evidence concerns the gene ELAVL1 and neoplasm.